Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.36M Sell
11,335
-1,119
-9% -$129K 0.35% 42
2025
Q4
$1.31M Sell
12,454
-592
-5% -$55.6K 0.34% 42
2025
Q3
$1.09M Sell
13,046
-82
-0.6% -$6.75K 0.33% 45
2025
Q2
$1.04M Buy
13,128
+2,388
+22% +$190K 0.31% 46
2025
Q1
$964K Buy
10,740
+617
+6% +$57.6K 0.33% 45
2024
Q4
$1.01M Buy
10,123
+933
+10% +$96.2K 0.34% 44
2024
Q3
$1.04M Sell
9,190
-2,794
-23% -$332K 0.35% 39
2024
Q2
$1.48M Buy
11,984
+1,331
+12% +$171K 0.55% 30
2024
Q1
$1.41M Buy
10,653
+97
+0.9% +$12K 0.5% 29
2023
Q4
$1.15M Buy
10,556
+1,070
+11% +$111K 0.45% 30
2023
Q3
$977K Buy
9,486
+2,902
+44% +$313K 0.41% 35
2023
Q2
$760K Buy
+6,584
New +$748K 0.32% 39

Other funds holding MRK

Hilltop Partners's MRK Position: Q1 2026 in Review

Hilltop Partners reduced its Merck (MRK) stake by 9% in Q1 2026, selling an estimated $129K and leaving 11,335 shares worth $1.36M. The position accounts for 0.35% of the portfolio, ranked #42.

Hilltop Partners first reported a position in MRK in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.48M in Q2 2024. 3,775 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Hilltop Partners held 11,335 shares of Merck worth $1.36M as of Q1 2026.
  • Hilltop Partners sold 1,119 Merck shares in Q1 2026, an estimated $129K.
  • Merck made up 0.35% of Hilltop Partners's portfolio in Q1 2026, its #42 holding.
  • Hilltop Partners first reported a position in Merck in Q2 2023 and has held it in 12 quarters since.
  • Hilltop Partners's Merck position peaked at $1.48M in Q2 2024.
  • 3,775 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Hilltop Partners's 13F filing for Q1 2026, filed 12 May 2026.